https://mugglehead.com/cabaletta-bio-rese-cel-acr-myositis-durability-safety/ Mugglehead Media en 2026-11-08T15:47:28.816Z Cabaletta Bio reports year-long rese-cel responses in six myositis patients NASDAQ: CABA, NASDAQ: CRSP, Cabaletta Bio, CRISPR Therapeutics, Cell therapy, Autoimmune disease, Myositis, Clinical trials, NASDAQ: IBB, iShares Biotechnology ETF https://mugglehead.com/johnson-johnson-icotrokinra-phase-3-psoriatic-arthritis/ Mugglehead Media en 2026-11-07T16:30:49.484Z Johnson & Johnson reports Phase 3 icotrokinra benefit in psoriatic arthritis NYSE: JNJ, NYSE: BMY, Johnson & Johnson, Bristol-Myers Squibb, Psoriatic arthritis, Phase 3, Icotrokinra, Oral therapies https://mugglehead.com/bioaffinity-technologies-third-quarter-lung-test-revenue-cash-funding/ Mugglehead Media en 2026-11-07T14:45:28.036Z bioAffinity Technologies grows lung-test sales but flags funding needs NASDAQ: BIAF, NASDAQ: BDSX, NASDAQ: IBB, bioAffinity Technologies, Biodesix, iShares Biotechnology ETF, Lung cancer, Diagnostics, Earnings, Going concern https://mugglehead.com/china-october-gold-reserves-demand/ Mugglehead Media en 2026-11-07T13:13:05.708Z China adds 25.8 tonnes of gold in October as reserve value falls TSE: AEM, NYSE: AEM, Agnico Eagle Mines, Gold, Central banks, China, Gold reserves https://mugglehead.com/relevant-gold-lewiston-29-drill-pad-approval/ Mugglehead Media en 2026-11-07T12:14:07.221Z Relevant Gold gets approval for 29 Lewiston drill-pad locations CVE: RGC, OTCMKTS: RGCCF, Relevant Gold Corp, Gold, Wyoming, Exploration drilling, Permits